Artiva Biotherapeutics, Inc. SEC filings ARTV

Artiva Biotherapeutics, Inc. has 232 filings in SEC EDGAR's recent list, going back to Jul 10, 2020. Its latest annual report, Form ARS, was filed on Aug 3, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (results of operations, exit or restructuring costs). The company's fiscal year ends on December 31.

Artiva Biotherapeutics, Inc. SEC filings
Form Description Filed Period
EFFECT Filing Aug 14, 2026 —
EFFECT Filing Aug 15, 2025 —
CORRESP Letter to the SEC Aug 13, 2025 —
UPLOAD Letter from the SEC Aug 11, 2025 —
SEC STAFF LETTER Filing Jul 19, 2024 —
EFFECT Filing Jul 18, 2024 —
CERT Filing Jul 18, 2024 —
CORRESP Letter to the SEC Jul 16, 2024 —
CORRESP Letter to the SEC Jul 16, 2024 —
8-A12B Filing Jul 16, 2024 —
CORRESP Letter to the SEC Jul 5, 2024 —
CORRESP Letter to the SEC Jun 28, 2024 —
UPLOAD Letter from the SEC Jun 21, 2024 —
DRS/A Filing Jun 10, 2024 —
DRSLTR Filing Jun 7, 2024 —
SEC STAFF LETTER Filing May 31, 2024 —
UPLOAD Letter from the SEC May 30, 2024 —
DRS Filing May 3, 2024 —
RW Filing Nov 1, 2022 —
D Filing Apr 5, 2021 —
DRS Filing Mar 2, 2021 —
D Filing Jul 10, 2020 —

Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ARTV (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
, Emerging growth company
SEC CIK
1817241

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.